The optimized use of KIRA compounds in ALS is expected to prevent or halt neurodegeneration by blunting terminal UPR in motoneurons, shifting deleterious RIDD activity to attenuated XBP1 splicing at levels contributing to homeostasis. Here, XBP1 is linked to amyotrophic lateral sclerosis.